UM Miller School of Medicine: Significant Published Analysis Supports New 'MRD' Endpoint for Multiple Myeloma
May 22, 2024
May 22, 2024
MIAMI, Florida, May 22 (TNSres) -- The University of Miami's Miller School of Medicine issued the following news:
By Charlotte Schubert
A key committee at the U.S. Food and Drug Administration voted in April to allow a new way to evaluate drugs for multiple myeloma. The method uses an endpoint called minimal residual disease (MRD) that promises to accelerate the development of new therapies.
The unanimous 12-0 committee decision was based in large part . . .
By Charlotte Schubert
A key committee at the U.S. Food and Drug Administration voted in April to allow a new way to evaluate drugs for multiple myeloma. The method uses an endpoint called minimal residual disease (MRD) that promises to accelerate the development of new therapies.
The unanimous 12-0 committee decision was based in large part . . .